Scott L Burrows insider trades: Spyre Therapeutics (SYRE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | SYRE | ↓ Sell | 25,000 | $90.47 | $2.3M | Direct | Oct 2, 2026 (1d) |
| Sep 2, 2026 | SYRE | ↓ Sell | 25,732 | $88.75 | $2.3M | Direct | Sep 3, 2026 (1d) |
| Aug 3, 2026 | SYRE | ↓ Sell | 7,500 | $95.57 | $717K | Direct | Aug 5, 2026 (2d) |
| Jul 1, 2026 | SYRE | ↓ Sell | 7,500 | $87.74 | $658K | Direct | Jul 2, 2026 (1d) |
| Jun 25, 2026 | SYRE | ↓ Sell | 15,000 | $87.13 | $1.3M | Direct | Jun 26, 2026 (1d) |
| Jun 1, 2026 | SYRE | ↓ Sell | 7,500 | $71.06 | $533K | Direct | Jun 3, 2026 (2d) |
| May 1, 2026 | SYRE | ↓ Sell | 12,500 | $71.37 | $892K | Direct | May 1, 2026 (0d) |
| Apr 1, 2026 | SYRE | ↓ Sell | 7,500 | $49.34 | $370K | Direct | Apr 3, 2026 (2d) |
| Mar 3, 2026 | SYRE | ↓ Sell | 2,500 | $40.65 | $102K | Direct | Mar 3, 2026 (0d) |
| Sep 2, 2025 | SYRE | ↓ Sell | 18,428 | $16.26 | $300K | Direct | Sep 3, 2025 (1d) |
| Sep 3, 2024 | SYRE | ↓ Sell | 18,531 | $28.17 | $522K | Direct | Sep 5, 2024 (2d) |
| Mar 6, 2023 | ARQT | ↓ Sell | 291 | $15.26 | $4K | Direct | Mar 8, 2023 (2d) |
| Mar 2, 2023 | ARQT | ↓ Sell | 1,850 | $15.90 | $29K | Direct | Mar 2, 2023 (0d) |
| Mar 7, 2022 | ARQT | ↓ Sell | 303 | $16.85 | $5K | Direct | Mar 7, 2022 (0d) |
| Mar 1, 2022 | ARQT | ↓ Sell | 420 | $17.75 | $7K | Direct | Mar 3, 2022 (2d) |
| Dec 27, 2021 | ARQT | ↓ Sell | 12,560 | $20.07 | $252K | Direct | Dec 28, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SYRE insiders
Open-market trades in the last 12 months
About Scott L Burrows's insider trades
Scott L Burrows is Chief Financial Officer at Spyre Therapeutics (SYRE). Since Dec 27, 2021, Scott has reported no open-market purchases and 16 sales worth $10.2M on SEC Form 4. In the last 12 months: 9 sales ($9.1M).
Their filings also include option exercises (10 filings), grants and awards (9 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SYRE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.